-
公开(公告)号:US20180201654A1
公开(公告)日:2018-07-19
申请号:US15727472
申请日:2017-10-06
申请人: Jae Jung
发明人: Jae Jung
IPC分类号: C07K14/005 , A61K38/16
CPC分类号: C07K14/005 , A61K38/162 , C12N2710/16422 , C12N2710/16433
摘要: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating ALL.
-
公开(公告)号:US20140073585A1
公开(公告)日:2014-03-13
申请号:US13971744
申请日:2013-08-20
申请人: Jae Jung
发明人: Jae Jung
IPC分类号: C07K14/005
CPC分类号: C07K14/005 , A61K38/162 , C12N2710/16422 , C12N2710/16433
摘要: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating ALL.
摘要翻译: 对应于vIRF4的aa202-216的vIRF4(卡波西 - 肉瘤相关疱疹病毒vIRF4)肽vif1和对应于vIRF4的a220-236的vif2是有效和选择性的HAUSP拮抗剂。 vif1和vif2肽强力抑制HAUSP DUB酶活性,最终导致p53介导的抗癌活性。 vif1和vif2肽及其同源物可用于治疗ALL。
-
公开(公告)号:US20230382953A1
公开(公告)日:2023-11-30
申请号:US18248291
申请日:2021-10-21
发明人: Yoshihiro Izumiya , Michiko Shimoda
IPC分类号: C07K14/005 , C07K16/18 , A61P35/00
CPC分类号: C07K14/005 , C07K16/18 , A61P35/00 , C12N2710/16422 , C07K2319/33 , C07K2319/10 , C07K2319/09 , C07K2317/622 , C07K2317/24 , C12N2710/16433
摘要: The present invention provides compositions and methods for treating a disease involving inappropriate or excessive cell proliferation or for treating an inflammatory condition or an autoimmune disease by inhibiting MYC activity in cells such as MYC-dependent cancer cells.
-
-